Click to edit Master title style
ESC 365 - Discussant review - Prospective Meta-Analysis of SGLT2 Inhibitor Randomized Trials in COVID-19
ESC 365 - Search
Enrique Santas on X: "DARE-19 trial #ACC21 @ACCinTouch Dapa did not reduce clinical endpoints in #COVID19, but excellent safety profile šÆ Do not discontinue SGLT2i in š„ for #COVID19 Full slideset available
Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial | Therapeutic Innovation & Regulatory Science
Kansas City Business Journal: Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious COVID-19 complications | Saint Luke's Health System
PDF) Effects of Dapagliflozin on Prevention of Major Clinical Events and Recovery in Patients with Respiratory Failure due to COVID ā19: The Design and Rationale for the DAREā19 study
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial - ScienceDirect
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial - ScienceDirect
Daily evidence digest
China Touts New Drug for Alleviating COVID-19 Now Undergoing Trials
View of Overview of the 81st Scientiļ¬c Sessions of the American Diabetes Association | British Journal of Diabetes
Saint Luke's Mid America Heart Institute and AstraZeneca initiate Phase III DARE-19 trial in COVID-19 patients | Saint Luke's Health System
ACC 2021: The DARE-19 Randomized Trial
Vaccini Covid: aziende sanitarie pronte a dare avvio alla campagna di prevenzione | Fiaso
Healio: DARE-19: Dapagliflozin could target key mechanisms activated in COVID-19 | Saint Luke's Health System
Kansas City Business Journal: Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious COVID-19 complications | Saint Luke's Health System
Ecco le Beta EVO Factory 2024, le trial pronto gara - Motociclismo Fuoristrada
Dapagliflozin fails to show a significant protective effect in COVID-19 - Medical Conferences
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial - ScienceDirect
DARE-19 Trial | PPT
DARE-19 results provide insight into SGLT2 inhibitor use in patients with type 2 diabetes and COVID-19 - ADA Meeting News
Click to edit Master title style
Ecco le Beta EVO Factory 2024, le trial pronto gara - Motociclismo Fuoristrada
